Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	40.46	45.79	35.44	11.36	55.74	32.59
Short-Term Investments	0.02	2.02	0.05	46.52	2.62	8.98
Cash & Short-Term Investments	40.49	47.81	35.49	57.88	58.36	41.56
Cash Growth	23.77%	34.69%	-38.67%	-0.83%	40.41%	35.31%
Accounts Receivable	0.13	0.64	0.75	0.3	50.84	0
Receivables	0.13	0.64	0.75	0.3	50.84	0
Prepaid Expenses	1.62	2.55	2.2	1.83	2.35	2.36
Restricted Cash	-	-	-	-	-	0.08
Total Current Assets	42.26	51	38.44	60	111.55	44
Property, Plant & Equipment	4.47	4.4	4.77	5.67	4.87	5.63
Goodwill	10.67	10.67	10.67	10.67	10.67	10.67
Other Intangible Assets	31.7	46.54	46.56	46.69	46.82	47.03
Other Long-Term Assets	0.54	0.61	0.58	0.63	0.63	0.62
Total Assets	89.64	113.22	101.02	123.66	174.55	107.95
Accounts Payable	1.52	1.17	2.05	2.39	3.54	2.61
Accrued Expenses	3.03	4.26	4.22	6.22	24.25	3.67
Short-Term Debt	-	-	-	-	-	0.52
Current Portion of Leases	1.07	1.15	0.88	0.95	0.83	0.76
Current Unearned Revenue	3.77	7.39	10.81	9.42	18.12	0.19
Other Current Liabilities	-	-	-	-	0.38	0.01
Total Current Liabilities	9.38	13.98	17.96	18.98	47.12	7.77
Long-Term Leases	1.56	1.36	2.07	2.94	1.97	2.54
Long-Term Unearned Revenue	12.46	14.43	18.69	27.73	32.45	-
Long-Term Deferred Tax Liabilities	0.27	0.27	0.27	2.08	2.08	2.08
Other Long-Term Liabilities	45.17	6.16	-	0	0.03	0.44
Total Liabilities	68.84	36.21	39	51.73	83.65	12.82
Common Stock	494.18	484.72	451.34	440.28	434.53	393.94
Retained Earnings	-467.85	-403.47	-384.86	-363.37	-337.1	-294.08
Comprehensive Income & Other	-4.29	-2.88	-3.07	-3.57	-5.21	-3.67
Total Common Equity	22.04	78.38	63.42	73.34	92.22	96.2
Minority Interest	-1.24	-1.37	-1.4	-1.4	-1.32	-1.07
Shareholders' Equity	20.8	77.01	62.02	71.94	90.9	95.13
Total Liabilities & Equity	89.64	113.22	101.02	123.66	174.55	107.95
Total Debt	2.62	2.51	2.95	3.9	2.8	3.83
Net Cash (Debt)	37.87	45.29	32.54	53.98	55.56	37.74
Net Cash Growth	26.38%	39.19%	-39.72%	-2.84%	47.22%	47.71%
Net Cash Per Share	0.16	0.23	0.19	0.32	0.34	0.25
Filing Date Shares Outstanding	230.33	228.36	188.53	170.15	169.71	161.64
Total Common Shares Outstanding	230.33	220.42	174.99	170.09	169.48	153.1
Working Capital	32.88	37.02	20.48	41.02	64.43	36.23
Book Value Per Share	0.10	0.36	0.36	0.43	0.54	0.63
Tangible Book Value	-20.33	21.17	6.19	15.98	34.73	38.5
Tangible Book Value Per Share	-0.09	0.10	0.04	0.09	0.20	0.25
Machinery	4.73	4.13	3.61	3.26	3.47	3.63
Leasehold Improvements	2.54	2.3	2.31	2.15	2.54	2.47

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q